Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA.
J Addict Med. 2012 Jun;6(2):118-23. doi: 10.1097/ADM.0b013e31824fceca.
Opioids are the most effective pain medication available, yet concerns about their safety may limit their administration to those in need. In efforts to identify analgesics with lower potential for abuse and dependence, recent evidence suggests that combinations of opioids with ultra-low doses of the opioid antagonist naloxone may enhance the analgesic effect with increased safety. This study investigated the use of buprenorphine (0.3 mg) plus ultra-low-dose naloxone (0.02 mg) (BUP + ULDN) as compared with buprenorphine alone (0.3 mg) (BUP) for the treatment of pain.
In a double-blind, placebo-controlled, randomized cross-over design, 12 study participants with lingering, noncancer pain received each medication intravenously for 5 days of dosing, separated by an intertrial interval of at least 7 days to avoid possible carryover effects.
We found no order effects and no differences between medications in pre- to postdose pain ratings, side effects, or adverse events.
These findings suggest that BUP + ULDN is not more effective in reducing pain than BUP.
阿片类药物是目前最有效的止痛药物，但人们对其安全性的担忧可能会限制其在有需要的人群中使用。为了寻找滥用和依赖潜力较低的镇痛药，最近的证据表明，阿片类药物与超低剂量阿片类拮抗剂纳洛酮联合使用可能会提高安全性的同时增强镇痛效果。本研究调查了丁丙诺啡（0.3 毫克）加超低剂量纳洛酮（0.02 毫克）（BUP+ULDN）与单独使用丁丙诺啡（0.3 毫克）（BUP）治疗疼痛的效果。
在一项双盲、安慰剂对照、随机交叉设计的研究中，12 名有持续非癌性疼痛的研究参与者接受了 5 天的静脉内给药，每种药物之间的试验间隔至少为 7 天，以避免可能的残留效应。
我们没有发现顺序效应，也没有发现两种药物在给药前后的疼痛评分、副作用或不良事件方面存在差异。
这些发现表明，BUP+ULDN 并不能比 BUP 更有效地减轻疼痛。
